AbsTrACT
Objectives approximately 5%-10% of adults with congenital heart disease (chD) develop pulmonary arterial hypertension (Pah), which affects life expectancy and quality of life. arrhythmias are common among these patients, but their incidence and impact on outcome remains uncertain. Methods all adult patients with Pah associated with chD (Pah-chD) seen in a tertiary centre between 2007 and 2015 were followed for new-onset atrial or ventricular arrhythmia. clinical variables associated with arrhythmia and their relation to mortality were assessed using cox analysis. results a total of 310 patients (mean age 34.9±12.3 years, 36.8% male) were enrolled. the majority had eisenmenger syndrome (58.4%), 15 .2% had a prior defect repair and a third had Down syndrome. at baseline, 14.2% had a prior history of arrhythmia, mostly supraventricular arrhythmia (86.4%). During a median follow-up of 6.1 years, 64 patients developed at least one new arrhythmic episode (incidence 3.47% per year), mostly supraventricular tachycardia or atrial fibrillation (78.1% of patients). arrhythmia was associated with symptoms in 75.0% of cases. the type of Pah-chD, markers of disease severity and prior arrhythmia were associated with arrhythmia during follow-up. arrhythmia was a strong predictor of death, even after adjusting for demographic and clinical variables (hr 3.41, 95% ci 2.10 to 5.53, p<0.0001). Conclusions arrhythmia is common in Pah-chD and is associated with an adverse long-term outcome, even when managed in a specialist centre.
InTrOduCTIOn
Adults with congenital heart disease (CHD) represent an expanding patient population requiring life-long tertiary care. 1 2 Approximately 5%-10% develop pulmonary arterial hypertension (PAH), with Eisenmenger syndrome being at the extreme end of the spectrum of PAH related to CHD (PAH-CHD). [3] [4] [5] PAH significantly affects the quality of life and life expectancy of these patients and is associated with significant morbidity. [5] [6] [7] [8] [9] [10] [11] One of the most common late complications in patients with CHD is arrhythmia, even though its incidence in the subgroup of patients with PAH-CHD remains uncertain. [12] [13] [14] [15] Arrhythmias in this cohort are likely to be related to the unique myocardial substrate in conjunction with longstanding pressure and/or volume overload, cyanosis and occasionally surgical scars. Arrhythmias, of supraventricular or ventricular origin, are often seen in PAH patients with more advanced disease and may compromise cardiac function leading to clinical deterioration. 16 17 However, little is known on the factors predisposing to the development of arrhythmia in PAH-CHD, and its prognostic impact.
The aim of our study was to determine the incidence of arrhythmia in adult patients with PAH-CHD and identify demographic and clinical risk factors. Moreover, we examined herewith the potential relation between arrhythmia and mortality in this population.
MeThOds study population
This is a retrospective, single-centre study enrolling patients with PAH-CHD aged ≥16 years followed in our tertiary centre between January 2007 and December 2015. Inclusion criteria were: 1) diagnosis of PAH associated with CHD according to current guidelines (previous right-sided cardiac catheterisation demonstrating a mean pulmonary artery pressure ≥25 mm Hg, pulmonary vascular resistance >3 WU and a mean pulmonary arterial capillary pressure ≤15 mm Hg) 18 ; for patients with Eisenmenger syndrome, resting or exercise-induced cyanosis, low velocity bidirectional or right to left shunting through the defect on echocardiography, in the absence of pulmonary stenosis, was deemed diagnostic and 2) follow-up of at least 6 months.
Demographic characteristics, cardiovascular risk factors, WHO functional class, ECG and echocardiographic features, blood tests and pharmacological history and history of prior arrhythmias were obtained for all patients at the time of their earliest full assessment within this period, which constituted their baseline. Patients were, thereafter, followed for new-onset supraventricular or ventricular arrhythmia. Patients with a prior history of permanent arrhythmia were included in the study and were followed for new-onset arrhythmia of a different type. Arrhythmias were detected by means of routine ECGs at follow-up, ECGs during hospitalisation, ambulatory ECG recordings, implantable loop recordings and/or device interrogation. Both supraventricular arrhythmias and arrhythmias of ventricular origin were included in the study. Supraventricular arrhythmias were specified to include: a) atrial fibrillation and b) supraventricular Congenital heart disease tachycardia (atrial ectopic tachycardia, atrial flutter, atrioventricular re-entrant tachycardia, atrioventricular nodal re-entrant tachycardia) as defined by current guidelines. Ventricular arrhythmias included non-sustained ventricular tachycardia (NSVT) and ventricular tachycardia (VT). Data on arrhythmia treatment with drugs, cardioversion (chemical or direct current) and transcatheter ablation were collected. As this was a retrospective analysis of data collected for routine clinical care and administrative purposes, individual informed consent was not required (UK National Research Ethics Service guidance).
statistical analysis
Analyses were performed with the use of R V.3.3.1 (http:// cran. r-project. org/) and the package survival. Data were presented as numbers, percentages or mean±SD. Baseline characteristics of patients with prior arrhythmia were compared with those without by Mann-Whitney U test or Χ 2 tests. Univariable Cox proportional regression analysis was used to identify clinical and demographic variables associated with arrhythmia during follow-up; variables significant on univariable analysis were used in the multivariable models. Moreover, univariable and multivariable Cox regression analysis was used to assess the relation between arrhythmia and death. Kaplan-Meier curves were plotted, and survival was compared between groups using the Logrank test. Arrhythmia was modelled as a time-dependent covariate, to account for patients who had not had arrhythmia prior to baseline but went on to develop arrhythmia during follow-up. This was used in the modified version of the Cox model with a 'start, stop' mechanism (counting process). The proportional hazards assumption was assessed using the cox. zph function, which is based on weighted residuals and no violation of the assumption was found. All p values were two-sided, and a p value of <0.05 was prespecified as indicative of statistical significance.
resulTs
A total of 310 patients (mean age 34.9±12.3 years, 36.8% male) were included in the study. The majority of patients had Eisenmenger syndrome (58.4%), 15.2% had a prior defect repair, whereas 26.5% belonged to other clinical CHD subgroups (PAH and left-right shunts: 22.5%, PAH-CHD with coincidental defects: 3.87%). Among patients with Eisenmenger syndrome, 46.9% had a post-tricuspid shunt, 49.2% had complex anatomy and only 3.9% had a pretricuspid shunt. Down syndrome was present in 94 (30.3%) patients, most with Eisenmenger syndrome (n=84, 89%). Other comorbidity present at baseline was systemic hypertension in 4.8%, diabetes mellitus in 1.6% and treated dyslipidemia in 1.6% of patients.
Forty-four patients (14.2%) had a prior history of arrhythmia at baseline, in most cases supraventricular arrhythmia (n=38, 86.4%); 16 patients (36.4%) had atrial fibrillation and 22 (50%) patients had supraventricular tachycardia. Ventricular arrhythmias included three (6.8%) patients with NSVT and three (6.8%) with VT. Only five (1.6%) patients had permanent atrial fibrillation at baseline. Eight (2.6%) patients had a permanent pacemaker, eight (2.6%) had an implantable cardioverter defibrillator device (ICD) and one (0.3%) had cardiac resynchronisation therapy defibrillator. Only 76 (24.5%) patients were on advanced therapy at baseline; however, during follow-up 269 (86%) patients were put on advanced therapy. Patients with prior arrhythmia at baseline were older than the remainder and had a higher incidence of prior syncope (table 1) .
Patients with Eisenmenger syndrome had the lowest prevalence of prior arrhythmia compared with the rest. The majority of patients with Down syndrome (98.9%) had no documented prior arrhythmia. Patients with prior arrhythmia were more likely to be on diuretics, beta-blockers, ACE inhibitors/angiotensin receptor blockers or anti-arrhythmic drugs. Patients with prior arrhythmia had a higher right atrial (RA) area on echocardiography, lower haemoglobin concentration, higher brain natriuretic peptide (BNP) and higher creatinine levels with a lower glomerular filtration rate compared with the remainder. There were no differences in sodium or albumin plasma concentration between patients with and without prior arrhythmia.
Arrhythmia during follow-up
During a median follow-up of 6.1 years, 64 patients (20.6%) developed at least one episode of new arrhythmia (incidence 3.47% per year, 95% CI 2.72 to 4.42) at a mean age of 46.8±11.8 years (table 2) .
Arrhythmia was documented by ECG recordings in 41 (64.1%), Holter monitoring in 19 (29%) and device interrogation in 4 (6.3%). The first new documented arrhythmia was supraventricular tachycardia in 35 (54.7%), atrial fibrillation in 15 (23.4%), NSVT in 11 (17.2%) and VT in 3 (4.7%) patients. The arrhythmia presented with symptoms at its onset in 48 (75.0%), while in 16 (25.0%) it was an incidental finding. Among patients with symptoms, arrhythmia manifested as palpitations in 37 (77.0%) patients, shortness of breath in 9 patients (18.8%), heart failure in 1 (2.1%) and ICD shock in 1 (2.1%).
Older patients were more likely to develop a new arrhythmia (figure 1). Patients on diuretics, beta-blockers, ACE inhibitors/ angiotensin receptor blockers and anti-arrhythmic medication and those with a history of systemic hypertension were more likely to have a new arrhythmia at follow-up. Patients less likely to develop arrhythmia included those with Eisenmenger syndrome compared with other clinical CHD subgroups (after defect correction and others), those with Down syndrome and patients on PAH therapies at baseline. Compared with the remainder, patients with a QRS duration longer than 150 ms were at increased risk of arrhythmia. Patients with a larger subpulmonary ventricle, lower tricuspid annular plane systolic excursion (TAPSE), larger RA area and a D-shaped systemic ventricle with a lower ejection fraction were also at higher risk of arrhythmia. Finally, patients with arrhythmia at follow-up had a higher BNP and creatinine concentration and lower haemoglobin and glomerular filtration rate, whereas there was no difference in resting systemic oxygen saturation or presence of pericardial effusion. In stepwise multivariable analysis including age, clinical CHD subgroup, history of prior arrhythmia, Down syndrome and systemic hypertension, only the first three variables remained in the model (table 3) . When adding each of QRS duration, TAPSE, RA area or laboratory variables in the multivariable model with age, clinical CHD subgroup and history of arrhythmia, none of the additional variables remained in the model.
None of the patients presenting with new-onset arrhythmia (first episode) died acutely during the index episode. Arrhythmia was sustained in 28 (43.7%) patients, whereas in 31 (48.4%) admission to hospital was required due to symptoms.
Treatment was required for arrhythmia in 49 (76.6%) patients. A rhythm control strategy was adopted in 34 (69.4%) patients and was successful in all cases: direct current cardioversion was employed in 11 (32.4%), chemical cardioversion in 5 (14.7%), overdrive pacing in 1 (2.9%) and ablation therapy in Figure 2 The incidence of arrhythmia in the overall pulmonary arterial hypertension with congenital heart disease (PAH-CHD) population (A) and PAH-CHD subgroups (B). The 'other' group contains patients with PAH and left-right shunts as well as patients with PAH-CHD and small (coincidental) defects.
Congenital heart disease
to 5.54, p<0.0001), whereas age and Down syndrome did not stay in the model (table 3) .
dIsCussIOn
Our data show that arrhythmia is common in patients with PAH-CHD, affecting one in six patients at 5 years of follow-up, and is associated with mid-term mortality. Numerous clinical variables were associated with arrhythmia, including the type of PAH-CHD, markers of disease severity and prior arrhythmia. While sinus rhythm can often be restored, high recurrence rates were suggestive of a significant and persisting arrhythmic substrate. Even though arrhythmia is more common in patients with advanced PAH-CHD, it is also recognised as a cause of decompensation in PAH, likely contributing to the strong relation between arrhythmia and death in our population. Patients with Eisenmenger syndrome were less likely to develop arrhythmia compared with patients with PAH-CHD with prior defect repair or those with relatively small defects (co-incidental) or left-to-right shunting. This observation underscores the significant differences in pathophysiology that exist within the spectrum of PAH-CHD. 19 20 Right ventricular (RV) adaptation to raised pulmonary arterial pressures has been suggested as the reason for the more benign natural history of Eisenmenger syndrome in adult patients, compared with other types of PAH. This is mostly observed in patients with post-tricuspid defects, in whom the RV is subjected to high pressures from birth or early infancy and may adapt better to chronic pressure overload. 19 Moreover, in comparison to patients with PAH-CHD after defect closure, patients with Eisenmenger syndrome seem to cope better with haemodynamic changes by shunting right-toleft (the defect acting as a relief valve), allowing for the RV to offload, while maintaining systemic cardiac output, although at the expense of cyanosis. 21 Most of the arrhythmias encountered in our study were supraventricular tachycardias, which are most likely of RA origin in patients with PAH. Indeed, RA size has been recognised as an important component in the diagnosis and risk stratification of PAH in recent guidelines. 18 RA dilatation is multifactorial in PAH-CHD and can be related to RV hypertrophy and pressure overload, and to the CHD itself, while prior surgery is associated with scarring that predisposes to macro-re-entry arrhythmias. In our study, arrhythmia was indeed more common in patients with a larger RA, larger and functionally impaired RV and higher BNP levels. Patients with previous defect closure and those with small defects often have a clinical presentation resembling idiopathic Congenital heart disease PAH, with more maladapted RVs and larger RAs, hence at higher risk of arrhythmia. 22 Moreover, atrial dilatation is common in patients with significant left-to-right shunting at ventricular (LA dilatation) and/or atrial (biatrial dilatation) level; hence, these patients may also be more prone to arrhythmia compared with patients with Eisenmenger syndrome. While all patients with PAH-CHD should be monitored closely for the onset of arrhythmia, our findings may help identify high-risk patients, requiring closer follow-up and more aggressive arrhythmia management.
Patients with Down syndrome had a lower incidence of arrhythmias compared with patients with no Down syndrome. This could be related to the fact that patients with Down syndrome were younger with the vast majority of them having Eisenmenger syndrome, hence potentially with a better cardiac adaptation to PAH. It should, however, be recognised that detecting arrhythmia may be difficult in patients with learning difficulties, who may not be able to describe palpitations and distinguish these from other symptoms. 23 Holter monitoring may also prove difficult, whereas implantable loop recorders often require sedation or general anaesthesia, with associated risks. It is, therefore, possible that arrhythmia has been underestimated in the Down syndrome subgroup. However, overall mortality was not higher among patients with Down syndrome, perhaps suggesting that important clinical arrhythmias were not missed in the Down syndrome subgroup.
Arrhythmia was strongly related to death in the mid-term and should be a warning sign for physicians caring for patients with PAH-CHD. Arrhythmias, both ventricular and supraventricular, can cause rapid deterioration of RV function and a drop in cardiac output with significant systemic effects. 24 Although there was no acute arrhythmic death in our study, prompt termination of arrhythmia should be the goal despite the risk associated with sedation or general anaesthesia if electrical cardioversion is pursued. The onset of arrhythmia should also be perceived as a marker of progression of the disease itself. In the context of a goal-oriented therapeutic strategy, the occurrence of an arrhythmia may prompt physicians, to consider uptitration and optimisation of PAH therapy. Moreover, other factors contributing to the occurrence of arrhythmia (eg, valve disease, decompensated heart failure) should be identified and addressed whenever possible.
Ventricular arrhythmia in our patients with PAH was rare as in previous studies. Patients with Eisenmenger syndrome are, however, known to be at risk of sudden cardiac death, which may well be arrhythmic in origin. 25 26 While ventricular arrhythmia is more likely to lead to sudden cardiac death, even fast supraventricular tachycardias can cause rapid haemodynamic deterioration in patients with advanced PAH-CHD and, thus, lead to sudden cardiac death. Unfortunately, unless the event leading to sudden cardiac death occurs in-hospital or is witnessed by medical staff, it can be challenging to distinguish arrhythmic from other causes of sudden death such as embolic, bleeding and/or vessel rupture.
limitations
Out study has several limitations relating to its retrospective design, which may have led to underestimation of true incidence of arrhythmia, even though all patients with PAH-CHD are assessed for palpitations and arrhythmia during routine follow-up. Particularly, it is possible that some non-sustained or asymptomatic arrhythmia remained undetected in patients with Down syndrome and perhaps in patients with less advanced disease. Moreover, arrhythmia may be responsible for cases of sudden, out-of-hospital death and could not be accounted for in this study. Future prospective studies may shed additional light on this common complication of PAH-CHD and examine whether a more aggressive arrhythmia management and escalation of PAH therapy could modulate outcome.
COnClusIOns
Arrhythmia is a common complication in the natural history of PAH-CHD, relates to type of PAH-CHD and is a marker of disease severity and a risk factor for mortality. Future studies are warranted to establish the optimal acute and long-term management of arrhythmia in this population, and in turn its impact on risk stratification models.
Key messages
What is already known on this subject? ► Approximately 5%-10% of adults with congenital heart disease (CHD) develop pulmonary arterial hypertension (PAH), which affects life expectancy and quality of life. ► Arrhythmias are common among these patients, but their incidence and impact on outcome remains uncertain.
What might this study add?
► This study showed that arrhythmia is common in patients with PAH-CHD affecting one in six patients at 5 years of follow-up and is associated with mid-term mortality. ► Numerous clinical variables were found to be associated with arrhythmia, including the type of PAH-CHD, markers of disease severity and prior arrhythmia. ► The high recurrence rates in this subgroup of patients are suggestive of a significant and persisting arrhythmic substrate.
how might this impact on clinical practice? ► Arrhythmia was strongly related to death and should be a warning sign for physicians caring for patients with PAH-CHD. ► The onset of arrhythmia should also be perceived as a marker of progression of the disease itself.
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